


# PRODUCT INFORMATION



## Src Kinase Inhibitor I

Item No. 14592

**CAS Registry No.:** 179248-59-0  
**Formal Name:** 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine  
**MF:** C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>  
**FW:** 373.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 223, 253, 344 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Src kinase inhibitor I is supplied as a crystalline solid. A stock solution may be made by dissolving the Src kinase inhibitor I in the solvent of choice, which should be purged with an inert gas. Src kinase inhibitor I is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of Src kinase inhibitor I in these solvents is approximately 2.5 and 0.25 mg/ml, respectively.

Src kinase inhibitor I is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, Src kinase inhibitor I should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Src kinase inhibitor I has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

The Src kinases constitute a family of non-receptor tyrosine kinases, which includes Src and Lck. Src kinase inhibitor I is a potent competitive inhibitor of both Src and Lck (IC<sub>50</sub> = 44 and 88 nM, respectively), as well as Csk and Yes.<sup>1,2</sup> It less effectively blocks the receptor tyrosine kinases VEGFR2 and C-fms (IC<sub>50</sub> = 0.32 and 30 μM), as well as a long list of serine/threonine kinases.<sup>1,2</sup> Src kinase inhibitor I also inhibits receptor-interacting protein-2 with an IC<sub>50</sub> value of 26 nM.<sup>2</sup>

### References

1. Tian, G., Cory, M., Smith, A.A., *et al.* Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. *Biochemistry* **40**(24), 7084-7091 (2001).
2. Bain, J., Plater, L., Elliot, M., *et al.* The selectivity of protein kinase inhibitors: A further update. *Biochem. J.* **408**(3), 297-315 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/16/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM